Key result
Serial hsCRP and IL-6 measurements post-MI show good reproducibility with ~66% between-individual variance.
Why the study?
Implementation of hsCRP and IL-6 measurement into clinical practice requires data on the reliability of such measurements due to physiological variation over time.
What is the reproducibility and within-individual variation of serial hsCRP and IL-6 measurements in post-myocardial infarction patients?
Observational (n=200)
What is the reproducibility and within-individual variation of serial hsCRP and IL-6 measurements in post-myocardial infarction patients?
Serial measurements of hsCRP and IL-6 show good reproducibility in post-myocardial infarction patients, suggesting that at least two subsequent measurements are sufficient for reliable clinical classification.
Supports stable hsCRP/IL-6 classification with limited sampling post-MI; leaves open whether serial measures improve risk stratification or outcomes.
BACKGROUND: Among the numerous emerging biomarkers, high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) have received widespread interest, and a large database has been accumulated on their potential role as predictors of cardiovascular risk. The concentrations of inflammatory biomarkers, however, are influenced, among other things, by physiological variation, which is the natural within-individual variation occurring over time. Implementation of hsCRP and IL-6 measurement into clinical practice requires data on the reliability of such measurements. METHODS: We serially measured hsCRP and IL-6 concentrations in up to 6 blood samples taken at monthly intervals from 200 post-myocardial infarction patients who participated in the AIRGENE study. RESULTS: The mean (SD) of the ln-transformed plasma concentrations (in milligrams per liter for hsCRP and nanograms per liter for IL-6) for all participants over all samples was 0.16 (1.04) for hsCRP and 0.76 (0.57) for IL-6, with no significant differences between men and women. The within-individual and analytical variance component for the ln-transformed hsCRP data was 0.37, and the between-individual variance component was 0.73. For the ln-transformed IL-6 data, these values were 0.11 and 0.22, respectively. A substantial part of the total variation in plasma hsCRP and IL-6 concentrations was explained by the between-individual variation (as a percentage of the total variance, 66.1% for the ln-transformed hsCRP data and 66.2% for the ln-transformed IL-6 data). For both markers, 2 measurements were needed to reach a sufficient reliability. CONCLUSIONS: Our results demonstrate considerable stability and good reproducibility for serial hsCRP and IL-6 measurements. Thus, there should be no major concern about misclassification in clinical practice if at least 2 subsequent measurements are taken.
No takes yet. Share an insight, caveat, or question.
Karakas et al. (2010) conducted an observational in post-myocardial infarction (n=200). Serial hsCRP and IL-6 measurements was evaluated on Between-individual variation as a percentage of total variance for hsCRP and IL-6.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: